Dubermatinib

N/A

Report date: 2023/02/07 20:00:24
NME

Base Information

Drug NameDubermatinib
Drug Alias NameTP-0903
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitors
TargetsAXL receptor tyrosine kinase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSumitomo Dainippon
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo Pharma America Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A